Cargando…
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model
Oncolytic virus (OV) therapy is a promising cancer immunotherapy, especially for cold tumors by inducing the direct lysis of cancer cells and initiation of potent antitumor response. Canerpaturev (C-REV) is an attenuated oncolytic herpes simplex virus-1, which demonstrated a potent antitumor effect...
Autores principales: | Abdelmoneim, Mohamed, Eissa, Ibrahim Ragab, Aboalela, Mona Alhussein, Naoe, Yoshinori, Matsumura, Shigeru, Sibal, Patricia Angela, Bustos-Villalobos, Itzel, Tanaka, Maki, Kodera, Yasuhiro, Kasuya, Hideki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747797/ https://www.ncbi.nlm.nih.gov/pubmed/36513720 http://dx.doi.org/10.1038/s41598-022-25065-w |
Ejemplares similares
-
Combination of Cetuximab and Oncolytic Virus Canerpaturev Synergistically Inhibits Human Colorectal Cancer Growth
por: Wu, Zhiwen, et al.
Publicado: (2019) -
Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials
por: Eissa, Ibrahim Ragab, et al.
Publicado: (2017) -
The Impact of Metformin on Tumor-Infiltrated Immune Cells: Preclinical and Clinical Studies
por: Abdelmoneim, Mohamed, et al.
Publicado: (2023) -
S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model
por: Miyajima, Noriyuki, et al.
Publicado: (2021) -
C-REV Retains High Infectivity Regardless of the Expression Levels of cGAS and STING in Cultured Pancreatic Cancer Cells
por: Morimoto, Daishi, et al.
Publicado: (2021)